Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is niacin ineffective? Or did AIM-HIGH miss its target?

Literature DB >> 22219232

Is niacin ineffective? Or did AIM-HIGH miss its target?

Abstract

The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) found, in an interim analysis, no cardiovascular benefit from taking extended-release niacin (Niaspan). In fact, there was a trend toward a greater risk of ischemic stroke, which did not reach statistical significance. But questions remain about this complex trial, which included intensive statin therapy in the active-treatment group and the control group.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2012 PMID： 22219232 DOI： 10.3949/ccjm.79a.11166

Source DB: PubMed Journal: Cleve Clin J Med ISSN： 0891-1150 Impact factor: 2.321

Keyword Cloud
Cited

14 in total

Review 1. Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors: K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal: Br J Pharmacol Date: 2012-11 Impact factor: 8.739

Review 2. Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?

Authors: Preethi Mani; Anand Rohatgi
Journal: Curr Atheroscler Rep Date: 2015-08 Impact factor: 5.113

Review 3. Regression of atherosclerosis: insights from animal and clinical studies.

Authors: Jonathan E Feig
Journal: Ann Glob Health Date: 2013-12-25 Impact factor: 2.462

4. Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.

Authors: Richard L Dunbar; Harsh Goel; Sony Tuteja; Wen-Liang Song; Grace Nathanson; Zeeshan Babar; Dusanka Lalic; Joel M Gelfand; Daniel J Rader; Gary L Grove
Journal: J Lipid Res Date: 2017-01-23 Impact factor: 5.922

5. HDL and cardiovascular risk: time to call the plumber?

Authors: Bernd Hewing; Kathryn J Moore; Edward A Fisher
Journal: Circ Res Date: 2012-10-12 Impact factor: 17.367

6. Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma.

Authors: Joseph A DiDonato; Ying Huang; Kulwant S Aulak; Orli Even-Or; Gary Gerstenecker; Valentin Gogonea; Yuping Wu; Paul L Fox; W H Wilson Tang; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal: Circulation Date: 2013-08-22 Impact factor: 29.690

Is niacin ineffective? Or did AIM-HIGH miss its target?

Review 1. Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Review 2. Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?

Review 3. Regression of atherosclerosis: insights from animal and clinical studies.

4. Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.

5. HDL and cardiovascular risk: time to call the plumber?

6. Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma.

Review 7. Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke.

Review 8. Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

9. In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.

Review 10. G protein-coupled receptors for energy metabolites as new therapeutic targets.